<DOC>
	<DOC>NCT01358721</DOC>
	<brief_summary>The purpose of this study is to evaluate the pharmacodynamic and biologic properties of BMS-936558 in subjects with metastatic renal cell carcinoma.</brief_summary>
	<brief_title>Phase I Biomarker Study (BMS-936558)</brief_title>
	<detailed_description>Intervention Model: Parallel Dose Comparison</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Women and men â‰¥ 18 years of age. Histologic confirmation of renal cell carcinoma with a clear cell component. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST). Tumor sites that can be accessed for repeat biopsies at acceptable clinical risk. Previously treated subjects must have failed at least 1 prior antiangiogenic agent and can have a maximum of 3 prior systemic treatments for renal cell cancer. Subjects in the treatment naive arm cannot have received prior systemic therapy for their renal cell carcinoma. Active or progressing brain metastases. Active concomitant. Active or history of autoimmune disease. Active use of systemic corticosteroids. Prior therapy with Cytotoxic T lymphocyteassociated antigen 4 (antiCTLA4), anti Programmed death1 (antiPD1), anti Programmed death ligand 1 (antiPDL1), anti Programmed death ligand 2 (antiPDL2), antiCD137, antiCD40, antiOX40 antibodies.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>